Pesquisar
Jazz Pharmaceuticals PLC
JAZZAdicionar à lista de desejos
225.790USD
-1.170-0.52%
Fechamento 05/08, 16:00（ET）Cotações atrasadas em 15 min
14.17BValor de mercado
547.58P/L TTM
Mais detalhes de Jazz Pharmaceuticals PLC Empresa
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Informações de Jazz Pharmaceuticals PLC
Código da empresaJAZZ
Nome da EmpresaJazz Pharmaceuticals PLC
Data de listagemJan 18, 2012
CEOGala (Renee D)
Número de funcionários2800
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 18
EndereçoFifth Floor, Waterloo Exchange
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal- -
Telefone35316347800
Sitehttps://www.jazzpharma.com/
Código da empresaJAZZ
Data de listagemJan 18, 2012
CEOGala (Renee D)
Executivos da empresa Jazz Pharmaceuticals PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.02%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
337.29K
-1.78%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.93K
-97.93%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
40.33K
+0.08%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
20.53K
-18.10%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.05K
-38.09%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
17.01K
-9.11%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.99K
+1.72%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
12.36K
-12.66%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.33K
+3.06%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.02%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
337.29K
-1.78%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.93K
-97.93%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
40.33K
+0.08%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
20.53K
-18.10%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.05K
-38.09%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Xywav
1.66B
38.83%
Epidiolex/epidyolex
1.06B
24.82%
Rylaze
402.92M
9.44%
Zepzelca
307.31M
7.20%
High-sodium oxybate AG royalty revenue
211.72M
4.96%
Outro
629.45M
14.75%
Por RegiãoUSD
Nome
Receita
Proporção
United States
3.83B
89.78%
Europe
341.12M
7.99%
All Others
94.87M
2.22%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Xywav
1.66B
38.83%
Epidiolex/epidyolex
1.06B
24.82%
Rylaze
402.92M
9.44%
Zepzelca
307.31M
7.20%
High-sodium oxybate AG royalty revenue
211.72M
4.96%
Outro
629.45M
14.75%
Distribuição de ações
Atualizado em: há 7 horas
Atualizado em: há 7 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.91%
Vanguard Portfolio Management, LLC
4.75%
Capital World Investors
4.25%
Vanguard Capital Management, LLC
4.22%
LSV Asset Management
3.91%
Outro
74.95%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
7.91%
Vanguard Portfolio Management, LLC
4.75%
Capital World Investors
4.25%
Vanguard Capital Management, LLC
4.22%
LSV Asset Management
3.91%
Outro
74.95%
Tipos de investidores
Investidores
Proporção
Investment Advisor
59.87%
Investment Advisor/Hedge Fund
32.31%
Hedge Fund
12.09%
Individual Investor
3.04%
Research Firm
2.90%
Venture Capital
1.86%
Pension Fund
1.62%
Bank and Trust
1.04%
Private Equity
0.27%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1229
70.31M
112.06%
-754.07K
2025Q4
1201
62.79M
103.33%
-9.05M
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
4.96M
8.06%
-50.61K
-1.01%
Dec 31, 2025
Capital World Investors
2.67M
4.33%
+111.73K
+4.37%
Dec 31, 2025
LSV Asset Management
2.46M
3.99%
-55.90K
-2.23%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
2.62M
4.26%
-213.35K
-7.52%
Dec 31, 2025
State Street Investment Management (US)
1.84M
2.99%
-30.09K
-1.61%
Dec 31, 2025
Franklin Advisers, Inc.
1.81M
2.95%
+1.13M
+164.20%
Dec 31, 2025
EcoR1 Capital, LLC
1.71M
2.77%
--
--
Dec 31, 2025
Fuller & Thaler Asset Management Inc.
1.68M
2.72%
+51.00K
+3.14%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
Ver Mais
Cambria Cannabis ETF
Proporção4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção3.11%
iShares U.S. Pharmaceuticals ETF
Proporção3.08%
Invesco Pharmaceuticals ETF
Proporção2.94%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.83%
Abacus FCF International Leaders ETF
Proporção2.69%
First Trust NASDAQ Pharmaceuticals ETF
Proporção2.51%
Clough Hedged Equity ETF
Proporção2.4%
Alger Russell Innovation ETF
Proporção2.12%
VictoryShares Small Cap Free Cash Flow ETF
Proporção1.77%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
